NZ630230A - Methods of treating pancreatic cancer - Google Patents
Methods of treating pancreatic cancerInfo
- Publication number
- NZ630230A NZ630230A NZ630230A NZ63023014A NZ630230A NZ 630230 A NZ630230 A NZ 630230A NZ 630230 A NZ630230 A NZ 630230A NZ 63023014 A NZ63023014 A NZ 63023014A NZ 630230 A NZ630230 A NZ 630230A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pancreatic cancer
- individual
- methods
- treating pancreatic
- effective amount
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 3
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 3
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ734971A NZ734971A (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751820P | 2013-01-11 | 2013-01-11 | |
| US201361752355P | 2013-01-14 | 2013-01-14 | |
| US13/794,480 US9511046B2 (en) | 2013-01-11 | 2013-03-11 | Methods of treating pancreatic cancer |
| PCT/US2014/011145 WO2014110443A1 (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630230A true NZ630230A (en) | 2017-09-29 |
Family
ID=51165317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630230A NZ630230A (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
| NZ734971A NZ734971A (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ734971A NZ734971A (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9511046B2 (enExample) |
| EP (1) | EP2943192B9 (enExample) |
| JP (3) | JP6342918B2 (enExample) |
| KR (1) | KR102205710B1 (enExample) |
| CN (2) | CN105025893A (enExample) |
| AU (1) | AU2013203699B2 (enExample) |
| BR (1) | BR112015016681A8 (enExample) |
| CA (1) | CA2897589C (enExample) |
| CY (1) | CY1124273T1 (enExample) |
| DK (1) | DK2943192T3 (enExample) |
| ES (1) | ES2878145T3 (enExample) |
| HK (1) | HK1216853A1 (enExample) |
| HR (1) | HRP20211062T1 (enExample) |
| HU (1) | HUE056612T2 (enExample) |
| IL (2) | IL239739A0 (enExample) |
| LT (1) | LT2943192T (enExample) |
| MX (1) | MX382017B (enExample) |
| NZ (2) | NZ630230A (enExample) |
| PL (1) | PL2943192T3 (enExample) |
| PT (1) | PT2943192T (enExample) |
| RS (1) | RS62076B1 (enExample) |
| SI (1) | SI2943192T1 (enExample) |
| SM (1) | SMT202100377T1 (enExample) |
| WO (1) | WO2014110443A1 (enExample) |
| ZA (1) | ZA201504877B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI3248600T1 (sl) | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| PL1931321T3 (pl) | 2005-08-31 | 2019-08-30 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| MX378130B (es) | 2009-04-15 | 2025-03-10 | Abraxis Bioscience Llc | Métodos y composiciones de nanopartículas sin priones. |
| PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| AU2011264590B2 (en) * | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| AU2016270558B2 (en) | 2015-06-04 | 2020-08-13 | Crititech, Inc. | Nozzle assembly and methods for use |
| KR102606071B1 (ko) | 2015-06-29 | 2023-11-27 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
| EP3316871A4 (en) * | 2015-06-30 | 2019-02-20 | The Trustees of Columbia University in the City of New York | TALKED COMPOSITION AND USES THEREOF |
| CA3018989A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| US20200071415A1 (en) * | 2017-03-17 | 2020-03-05 | Imclone Llc | Combination therapy for pancreatic cancer |
| CN110730679A (zh) | 2017-06-09 | 2020-01-24 | 克里蒂泰克公司 | 囊内注射抗肿瘤颗粒治疗上皮囊肿 |
| JP6840869B2 (ja) | 2017-06-14 | 2021-03-10 | クリチテック，インコーポレイテッド | 肺障害の治療方法 |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| KR102837015B1 (ko) | 2018-03-20 | 2025-07-23 | 아브락시스 바이오사이언스, 엘엘씨 | mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법 |
| GB201908352D0 (en) * | 2019-06-11 | 2019-07-24 | Innovation Ulster Ltd | Sonodynamic therapy |
| EP4007640A4 (en) * | 2019-08-01 | 2023-10-04 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| EP4100035A1 (en) * | 2020-02-04 | 2022-12-14 | Swedish Orphan Biovitrum AB (publ) | Pdac treatment regimen |
| AU2023435819A1 (en) * | 2023-03-09 | 2025-10-02 | Minneamrita Therapeutics Llc | Drug combination for treatment of pancreatic cancer |
| CN117099681B (zh) * | 2023-08-28 | 2024-07-05 | 南京农业大学 | 一种利用紫杉醇加倍玉米单倍体的方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| DK0693924T4 (da) | 1993-02-22 | 2008-08-04 | Abraxis Bioscience Inc | Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| NZ502500A (en) | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| CA2684454A1 (en) | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| KR20150108943A (ko) | 2002-12-09 | 2015-09-30 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2012201568B2 (en) | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI3248600T1 (sl) | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| US7691392B2 (en) | 2005-04-29 | 2010-04-06 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either |
| EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| PL1931321T3 (pl) | 2005-08-31 | 2019-08-30 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| JP2007297339A (ja) * | 2006-04-29 | 2007-11-15 | Torii Yakuhin Kk | 癌を治療又は検査するための医薬 |
| EP2056812A1 (en) | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| LT2481402T (lt) | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| WO2008150532A1 (en) | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| RU2010145529A (ru) | 2008-04-10 | 2012-05-20 | АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) | Композиции гидрофобных производных таксана и их применение |
| ES2588194T3 (es) * | 2008-04-11 | 2016-10-31 | Seattle Genetics, Inc. | Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres |
| MX2011006167A (es) | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
| GB0900555D0 (en) | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| JP5725563B2 (ja) | 2009-03-13 | 2015-05-27 | アブラクシス バイオサイエンス， エルエルシー | チオコルヒチン誘導体との組み合わせ療法 |
| CA2758200A1 (en) | 2009-04-10 | 2010-10-14 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| MX378130B (es) | 2009-04-15 | 2025-03-10 | Abraxis Bioscience Llc | Métodos y composiciones de nanopartículas sin priones. |
| CA2960887C (en) * | 2009-05-28 | 2018-09-04 | Abraxis Bioscience, Llc | Use of 2 anti-sparc antibodies to predict response to chemotherapy |
| MX340670B (es) * | 2009-08-25 | 2016-07-20 | Abraxis Bioscience Llc * | Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog. |
| JP2011079788A (ja) * | 2009-10-08 | 2011-04-21 | Oita Univ | 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬 |
| NZ601324A (en) * | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| JP2013523712A (ja) | 2010-03-30 | 2013-06-17 | クラヴィス・ファルマ・アーエスアー | ゲムシタビン−５’−エライデートを用いて癌を治療又は緩和するための方法及び組成物 |
| ES2639038T3 (es) | 2010-06-02 | 2017-10-25 | Abraxis Bioscience, Llc | Métodos para el tratamiento de cáncer de vejiga |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| AU2011264590B2 (en) | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| MX377729B (es) | 2013-02-11 | 2025-03-11 | Abraxis Bioscience Llc | Métodos para tratamiento del melanoma. |
| US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| WO2014143613A1 (en) | 2013-03-13 | 2014-09-18 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US20170202782A1 (en) | 2014-04-06 | 2017-07-20 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| IL256326B2 (en) | 2015-06-29 | 2024-09-01 | Abraxis Bioscience Llc | Biomarkers for nanoparticle compositions |
| KR102606071B1 (ko) | 2015-06-29 | 2023-11-27 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
| AU2016287508B2 (en) | 2015-06-29 | 2021-10-14 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
-
2014
- 2014-01-10 SM SM20210377T patent/SMT202100377T1/it unknown
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
- 2014-01-10 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active Active
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en not_active Ceased
- 2014-01-10 MX MX2015008898A patent/MX382017B/es unknown
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
-
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
-
2016
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
-
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
-
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
-
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
-
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
-
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630230A (en) | Methods of treating pancreatic cancer | |
| MY188911A (en) | Methods of treating bladder cancer | |
| NZ604031A (en) | Methods of treatment of pancreatic cancer | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| NZ602382A (en) | Methods of treatment of hepatocellular carcinoma | |
| GB201114051D0 (en) | Compounds and their uses | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
| PH12013502487A1 (en) | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents | |
| EA201690528A1 (ru) | Способы лечения злокачественной опухоли непрерывной инфузией кофермента q10 | |
| MY169330A (en) | Method for inhibition of deubiquitinating activity | |
| MX2020013730A (es) | Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario. | |
| MX363746B (es) | Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. | |
| TN2014000086A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| NZ710600A (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| WO2016081773A3 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| IN2015DN03329A (enExample) | ||
| MX2016006207A (es) | Fibra repelente de suciedad y metodos para fabricar la misma. | |
| PH12014502109A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| MY188937A (en) | Compositions for treating subterranean formations | |
| UA86152U (ru) | Способ лечения больных хроническим гепатитом с, которые имеют противопоказания к интерферонотерапии, и/или нон-респондеров | |
| NZ735027A (en) | Anti-cancer activity of (e)-1-(3’,4’-dimethoxyphenyl) butadiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2019 BY AJ PARK Effective date: 20180130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2020 BY COMPUTER PACKAGES INC Effective date: 20181218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20191218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2022 BY CPA GLOBAL Effective date: 20201203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2023 BY CPA GLOBAL Effective date: 20211202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2024 BY CPA GLOBAL Effective date: 20221202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2025 BY CPA GLOBAL Effective date: 20231130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241128 |